Protalix publishes corporate presentation highlighting Elfabrio EU monthly dosing approval

Protalix Biotherapeutics, Inc. +1.33% Pre

Protalix Biotherapeutics, Inc.

PLX

2.28

2.28

+1.33%

0.00% Pre
  • Protalix outlined commercialization progress for Elfabrio in Fabry disease, highlighting EU availability of a 2 mg/kg every-4-weeks option.
  • Company reported FY 2025 revenue of USD 53 million.
  • Cash and cash equivalents totaled USD 30 million as of Dec. 31, 2025.
  • Protalix cited receipt of a USD 25 million milestone payment from Chiesi tied to the EU dosing milestone for Elfabrio.
  • Pipeline focus centered on PRX-115 for uncontrolled gout, with Phase 2 enrollment ongoing and topline data targeted for 2H 2027.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Protalix BioTherapeutics Inc. published the original content used to generate this news brief on March 31, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.